Stock events for Taysha Gene Therapies, Inc. (TSHA)
Over the past six months, Taysha Gene Therapies' stock price has seen significant movement, with a 38.48% increase in the last six months and a 168.82% increase over the past year. TSHA-102 received FDA Breakthrough Therapy designation for Rett syndrome in October 2025. Taysha regained full global rights to its TSHA-102 Rett syndrome program after an option agreement with Astellas expired in October 2025. The company reported its Third Quarter 2025 financial results and provided a corporate update on November 4, 2025. Taysha dosed the first patient in the REVEAL pivotal trial for TSHA-102 in Q4 2025. Consensus revenue estimates fell by 11% in November 2025, but the price target increased by 7.9% to US$10.54. Needham reiterated a Buy rating on the stock with a $10 price target in January 2026. The stock traded within a 52-week range of $1.13 to $5.91 in February 2026. The company approved the issuance of restricted stock units and stock options to a new employee on March 2, 2026.
Demand Seasonality affecting Taysha Gene Therapies, Inc.’s stock price
As a clinical-stage biotechnology company, Taysha Gene Therapies does not currently have commercialized products generating sales revenue; therefore, there is no demand seasonality. The company's financial engine is fueled by non-product sources such as collaboration and licensing agreements, and capital raises to fund its research and development pipeline.
Overview of Taysha Gene Therapies, Inc.’s business
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing and commercializing AAV-based gene therapies for severe monogenic CNS diseases. Their lead program, TSHA-102, is in development for Rett syndrome and is currently in a Phase I/II clinical trial. Taysha also has rights to TSHA-120 for giant axonal neuropathy and other pipeline candidates for various diseases. The company generates revenue from collaborations and licensing agreements.
TSHA’s Geographic footprint
Taysha Gene Therapies is headquartered in Dallas, Texas, United States. The company's lead program, TSHA-102 for Rett syndrome, targets an estimated 15,000 to 20,000 patients across the US, Europe, and the UK.
TSHA Corporate Image Assessment
Taysha Gene Therapies has maintained a positive brand reputation over the past year, driven by promising clinical developments for TSHA-102. The FDA's Breakthrough Therapy designation for TSHA-102 significantly bolstered its standing. Analysts have a "Moderate Buy" consensus rating for the company, indicating optimism about its gene therapy innovations and pipeline potential. The company's focus on addressing severe monogenic CNS diseases positions it as a leader in a high-unmet-need area.
Ownership
Taysha Gene Therapies' ownership is primarily institutional, with institutional shareholders holding 98.17% of the company's stock as of February 27, 2026. Ra Capital Management LP, Avoro Capital Advisors LLC, and BlackRock Inc. are among the major institutional owners. Individual investors and insiders also hold shares, with insiders owning 11.62% of the company. Paul B Manning owns the most shares among individual investors.
